Nonviral vector gene modification of stem cells for myocardial repair.
Therapeutic angiogenesis and myogenesis restore perfusion of ischemic myocardium and improve left ventricular contractility. These therapeutic modalities must be considered as complementary rather than competing to exploit their advantages for optimal beneficial effects. The resistant nature of cardiomyocytes to gene transfection can be overcome by ex vivo delivery of therapeutic genes to the heart using genetically modified stem cells. This review article gives an overview of different vectors and delivery systems in general used for therapeutic gene delivery to the heart and provides a critical appreciation of the ex vivo gene delivery approach using genetically modified stem cells to achieve angiomyogenesis for the treatment of infarcted heart.
Haider
Husnain K
HK
Department of Pathology and Laboratory Medicine, University of Cincinnati, OH 45267-0529, USA.
Elmadbouh
Ibrahim
I
Jean-Baptiste
Michel
M
Ashraf
Muhammad
M
D000818:Animals; D002478:Cells, Cultured; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000737:chemistry; D006801:Humans; D024510:Muscle Development / Q000235:genetics; D009203:Myocardial Infarction / Q000378:metabolism / Q000628:therapy*; D009204:Myocardial Revascularization / Q000379:methods*; D009206:Myocardium / Q000737:chemistry / Q000166:cytology / Q000378:metabolism* / Q000473:pathology; D032383:Myocytes, Cardiac / Q000166:cytology / Q000378:metabolism / Q000473:pathology; D018919:Neovascularization, Physiologic / Q000235:genetics; D051381:Rats; D012038:Regeneration / Q000235:genetics; D033581:Stem Cell Transplantation; D013234:Stem Cells / Q000737:chemistry / Q000378:metabolism*; D019076:Transgenes / Q000235:genetics